Kappa-Opioid Receptor Antagonism Prolongs the Antidepressant Effects of Ketamine in Adult Mice with Depression-like Behavior Induced by Adolescent Chronic Unpredictable Stress.
📄 Abstract
Major depressive disorder (MDD) is a highly prevalent psychiatric illness for which rapid-acting antidepressants such as ketamine provide only transient benefit. Because κ-opioid receptor (KOR) signaling contributes to stress-related dysphoria and impaired neuroplasticity, we examined whether KOR antagonism could prolong ketamine's antidepressant-like effects in a mouse model of adolescent chronic unpredictable stress (CUS). Male
Confidence:
0.21
· 11 полей извлечено
Идентификация (6 полей)
Target
Kappa-Opioid Receptor
1.00
Alt. target
KOR
1.00
Protein family
Opioid Receptor
0.90
Functional class
G protein-coupled receptor
0.80
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
—
0.00
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
KOR antagonism prolonged ketamine's antidepressant-like effects in a mouse model of adolescent chronic unpredictable stress
0.90
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
adult mice with depression-like behavior induced by adolescent chronic unpredictable stress
0.90
Diet/model
adolescent chronic unpredictable stress (CUS) mouse model
0.90
Клиника (11 полей)
Drug
ketamine
0.95
Indication
major depressive disorder
0.90
Patient subgroups
treatment-resistant depression
0.80
Safety concerns
side effects over time with repeated treatment
0.70
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00